X0303 4 2010-12-15 0001369868 China Biologic Products, Inc. CBPO 0001414565 Warburg Pincus Private Equity X, L.P. C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001451560 WARBURG PINCUS X PARTNERS, L.P. C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001414561 Warburg Pincus X, L.P. C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001414564 Warburg Pincus X LLC C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001322709 Warburg Pincus Partners LLC C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001162870 WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0000929408 WARBURG PINCUS & CO 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001239318 KAYE CHARLES R C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001220638 LANDY JOSEPH C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 Common Stock 2010-12-15 4 P 0 41000 15.8267 A 4711000 D Common Stock 2010-12-15 4 P 0 9000 16.5366 A 4720000 D Common Stock 2010-12-16 4 P 0 91735 16.635 A 4811735 D Common Stock 2010-12-16 4 P 0 8265 17.35 A 4820000 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.33 to $16.19, inclusive. The Warburg Pincus Reporting Persons (as defined below) undertake to provide to any security holder of China Biologic Products, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.49 to $16.84, inclusive. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.12 to $17.10, inclusive. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.28 to $17.50, inclusive. Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X") is the holder of an aggregate of 4,670,580 shares of Common Stock. Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X" and together with WP X, the "Funds") is the holder of an aggregate of 149,420 shares of Common Stock. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Warburg Pincus X, L.P., a Delaware limited partnership and the sole general partner of each of the Funds ("WP X LP"), Warburg Pincus X LLC, a Delaware limited liability company ("WP X LLC") and the sole general partner of WP X LP, Warburg Pincus Partners, LLC, a New York limited liability company ("WPP LLC") and the sole member of WP X LLC, Warburg Pincus LLC, a New York limited liability company ("WP LLC") that manages each of the Funds, Warburg Pincus & Co., a New York general partnership ("WP") and the managing member of WPP LLC, (cont'd on Footnote 6) and Messrs. Charles R. Kaye and Joseph P. Landy is a "Reporting Person" and collectively, the "Warburg Pincus Reporting Persons." Information with respect to each of the Warburg Pincus Reporting Persons is given solely by such Warburg Pincus Reporting Persons, and no Warburg Pincus Reporting Person has responsibility for the accuracy or completeness of information supplied by another Warburg Pincus Reporting Person. Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934, as amended, each of the Warburg Pincus Reporting Persons, other than the WP X and WPP X, herein states that this Statement shall not be deemed an admission that he or it is the beneficial owner of any of the shares of Common Stock covered by this Statement. Each of WP X LP, WP X LLC, WP Partners, WP, WP LLC, and Messrs. Kaye and Landy disclaims beneficial ownership of the Common Stock, except to the extent of its or his pecuniary interest in such shares of Common Stock. /s/ Scott A. Arenare, Partner. See Exhibit 1 for complete Joint Filers' Signatures 2010-12-17